CORRESPONDENCE
We read with interest the News & Views article by Palesh and Koopman (Posttraumatic stress disorder-prevalent and persistent. Nat. Rev. Clin. Oncol. 10, 252-254; 2013) 1 that focused on a recent report by vin-Raviv et al. 2 on racial differences in post-traumatic stress disorder (PTSD). Both the commentary and the underlying paper unquestioningly present the common-sense picture that, for most women with breast cancer, distress is highest at or around the time of diagnosis, but steadily declines thereafter. 3, 4 This view has prevailed in the literature for over 15 years. 5 However, all but a handful of the studies describing the psychosocial outcomes in patients with cancer used whole-group analy ses of longitudinal data, which-in reality-were serial cross-sectional studies. Although simply, and possibly correctly, reporting declining proportions of distressed patients at different time points, these proportionate studies misrepresent what is a more complex response. Few studies have adopted different analytical approaches that decompose samples into smaller subsets of trajectories. [6] [7] [8] These reports suggest a very different picture to that implied by the prevailing view. Firstly, most patients with cancer experience persistent low levels of distress (or PTSD) across the 6 months follow ing breast (or other) cancer (or other traumatic) 9 diagnoses. There are critical time points-such as diagnosis, surgery and treatment c essation-but acute distress responses probably quickly revert. Second, only a small minority of patients (typically around 20%) follow the 'classic' high-to-low pattern of distress that begins with a high level of stress and declines s teadily over time. In fact, a compara ble proportion (20%) of patients begin with low distress that increases over time, typically at 1-3 months, but then declines by 8 months. Furthermore, approximately 12-25% of patients experience persistently high levels of distress that continue for at least 8 months and for whom, 6 years later, psychosocial outcomes remain poor compared with their peers. 10 1 the IES has been criticized 12 for being non specific, omitting symptom clusters important in PTSD diagnosis and specific symptoms that include hyperarousal. To use a measure of what amounts to general distress to define PTSD risks extensively over-pathologizing what might be considered a 'normal' distress response. 12 Finally, Palesh and Koopman 1 recommend screening for PTSD, but ignore the thorny questions of when and for whom. Different people react at different time points and, unless screening is done constantly, it will be largely ineffective. Given the high cost of psychological interventions, most patients receiving a positive screen might be further burdened by more expensive, and possibly unnecessary, treatments. Unless we can distinguish those likely to experience chronic high distress from those on other distress trajectories, PTSD screening will inevitably be an extremely costly endeavor, which would be a more important trauma for many.
Oncologists must understand these important factors when presented with a distressed patient newly diagnosed with cancer. Patients might be distressed. However, not all distress signifies PTSD and not all distress requires an intervention. Care decisions will likely be affected by a distressed patient and, therefore, physicians must be informed. 
